Geron Corporation (NASDAQ:GERN) is a biopharmaceutical company focused on developing and commercializing innovative therapeutics for cancer treatment. The company's primary product candidate is imetelstat, a telomerase inhibitor, which is in clinical trials for hematologic myeloid malignancies. Geron operates in a competitive landscape with peers like Stem, Inc., Agenus Inc., and Exelixis, Inc., each with varying degrees of capital efficiency.

Geron Corporation's financial metrics reveal a challenging situation. With a Weighted Average Cost of Capital (WACC) of 8.25% and a Return on Invested Capital (ROIC) of -34.35%, Geron is not generating returns that exceed its cost of capital. This negative ROIC suggests inefficiencies in how the company utilizes its capital, which is a concern for investors looking for effective capital management.

In comparison, Stem, Inc. has a WACC of 4.61% and an ROIC of -0.09%. While Stem also has a negative ROIC, its ROIC to WACC ratio of -0.02 is closer to zero than Geron's -4.16. This indicates that Stem is slightly more efficient in its capital utilization, although it still falls short of covering its cost of capital.

Agenus Inc. presents a stark contrast with a WACC of 88.78% and an impressive ROIC of 302.53%. Its ROIC to WACC ratio of 3.41 highlights its strong ability to generate returns well above its cost of capital. This makes Agenus the most efficient among its peers in terms of capital utilization, suggesting robust growth potential.

Exelixis, Inc. also demonstrates effective capital utilization with a WACC of 6.63% and an ROIC of 18.19%. Its ROIC to WACC ratio of 2.74 indicates a solid performance, though not as high as Agenus. Exelixis's positive ROIC suggests it is effectively using its capital to generate returns, making it an attractive option for investors seeking efficient capital management.